Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colon Cancer: Incidence, Etiology, and Management

John H. Heinzerling, Sergio Huerta

Research output: Contribution to journalArticle

71 Scopus citations


Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.

Original languageEnglish (US)
Pages (from-to)334-337
Number of pages4
JournalCurrent Surgery
Issue number5
Publication statusPublished - Sep 2006



  • acute abdomen
  • Avastin
  • Bevacizumab
  • bowel perforation
  • chemotherapy
  • colon cancer
  • immunotherapy

ASJC Scopus subject areas

  • Surgery

Cite this